Therapeutic Area Commitment


Today and tomorrow

We’re committed to helping reduce the suffering caused by cancer and alleviating the effects of chronic inflammatory diseases. In nearly four decades of developing biologics, we’ve delivered a portfolio of innovative medicines that have made a positive impact across these therapeutic areas.

We’ll continue research and development in these areas and others, with the goal of creating more and better treatment options for patients.


The highest high-quality medicines

As we strive to meet the needs of patients with chronic inflammatory diseases or cancer, we’ve made it our mission to deliver only high-quality medicines. That’s because there’s too much on the line when it comes to these life-altering diseases.

We’ve been doing it for decades with our novel biologic medicines, and we’ll maintain that standard with our biosimilars. Patients and caregivers can count on us for the quality that they expect and depend on.


Moving forward

We’re committed to building a future with a more sustainable healthcare system. We believe that all patients should have cost-effective access to the medicines they’re prescribed. That’s why we’re expanding access with our portfolio of biosimilar medicines for cancer and inflammatory diseases.


Previous: impact of biosimilars